Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Vivos Therapeutics Inc (VVOS) provides innovative solutions for sleep-disordered breathing through its proprietary oral appliance therapy and integrated clinical protocols. This news hub offers investors and healthcare professionals direct access to official announcements, financial disclosures, and progress updates on the company's non-invasive treatment alternatives for obstructive sleep apnea.
Our curated collection features regulatory filings, partnership announcements, clinical trial updates, and technology developments. Users will find timely information about the Vivos System implementation, insurance coverage expansions, and research collaborations within the sleep medicine field.
The page organizes content by key categories including quarterly earnings reports, FDA communications, provider network growth, and peer-reviewed study publications. Each update maintains factual accuracy while highlighting the company's position in the $7 billion sleep apnea treatment market.
Bookmark this page for streamlined tracking of Vivos' progress in commercializing its oral appliance technology and expanding its licensed provider network. Check regularly for new developments in patient outcomes data and healthcare provider adoption rates across North America.
Vivos Therapeutics, a medical technology company, announced the opening of its third Pneusomnia Sleep Center in Toluca Lake, California, in May 2022. This center aims to provide a comprehensive treatment approach for obstructive sleep apnea (OSA)
Vivos Therapeutics (NASDAQ: VVOS) reported a 33% increase in fourth quarter revenue, totaling $4.4 million, and a 29% increase for the full year, reaching $16.9 million. The growth was driven by increased appliance sales and new revenue sources. The total number of oral appliance arches sold rose to 2,707 in Q4 and 11,355 for the full year. Gross profit was $3.1 million in Q4, with a gross margin of 71%. Vivos also secured its mmRNA device's acceptance by Medicare and registered products with Health Canada. Management will hold a conference call today at 5:00 pm ET.
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company, will release its fourth quarter and full year 2021 financial results today, March 31, 2022, following market close. The company will host a conference call at 5:00 PM ET to discuss the results and outline its growth strategy. Vivos specializes in innovative treatments for dentofacial abnormalities and obstructive sleep apnea, with its method having been effective for approximately 25,000 patients globally.
Vivos Therapeutics (NASDAQ: VVOS) has been recognized by Fast Company as the 9th most innovative medical device company in 2022. The company specializes in non-surgical and non-invasive treatments for dentofacial abnormalities and obstructive sleep apnea (OSA). Their proprietary technique, the Vivos Method, offers a 12-24 month treatment option that significantly improves airway conditions. Currently, over 25,000 patients have been treated using this method, addressing a market where over 1 billion people suffer from sleep apnea, many of whom remain undiagnosed.
Vivos Therapeutics has announced a rebranding of its proprietary treatment system to The Vivos Method, aimed at enhancing clarity and approachability for dentists and patients. This method combines customized oral appliances with multidisciplinary protocols to treat obstructive sleep apnea (OSA) in 12 to 24 months, offering a non-invasive alternative to traditional CPAP machines and surgeries. Vivos reports success with over 25,000 patients treated globally by more than 1,450 dentists. The updated website provides extensive information, including patient testimonials and partnership opportunities.
Vivos Therapeutics, a medical technology company focused on innovative treatment for dentofacial abnormalities and obstructive sleep apnea, announced CEO Kirk Huntsman's participation in upcoming conferences. Huntsman will present at the Q1 Virtual Investor Summit on March 8, 2022, at 4:15 PM ET and will engage in a fireside chat at the 34th Annual ROTH Conference on March 15, 2022, at 8:30 AM PT. Recordings of the presentations will be available on Vivos' website. The company aims to provide non-surgical, cost-effective solutions for sleep apnea, having treated about 25,000 patients worldwide.
Vivos Therapeutics (NASDAQ: VVOS) will present new clinical data at the World Sleep Congress in Rome from March 11-16, 2022. Dr. Seth Heckman, MD will lead the presentation on March 15, focusing on patient outcomes utilizing the Vivos Method for treating obstructive sleep apnea (OSA). The Vivos Method offers a non-surgical, effective solution, with 97% of patients achieving clinical objectives. The Medical Advisory Board, formed in October 2021, aims to enhance evidence-based practices in sleep medicine.
Vivos Therapeutics has filed a new U.S. patent application for enhanced clinical methods in treating obstructive sleep apnea (OSA) using its proprietary Vivos Method. Early data show a significant 58% improvement in Apnea Hypopnea Index (AHI) score reductions among patients treated with the revised protocols. This initiative is part of Vivos' Continuous Clinical Improvement Program aimed at refining treatment and optimizing patient outcomes. Currently, around 54 million Americans suffer from sleep apnea, highlighting the necessity for effective, non-invasive treatment alternatives.
Vivos Therapeutics (NASDAQ: VVOS) announced a significant surge in its Home Sleep Apnea Tests (HST) for the three months ending December 31, 2021.
Key metrics include an 18x increase in total HSTs, a 5.7x rise in the number of dentists administering these tests, and a 3x increase in average tests per dentist.
This performance led to a renegotiated agreement with SleepImage, reducing costs and establishing a recurring revenue model. With over one billion people suffering from sleep apnea, Vivos aims to leverage its new arrangement to improve patient access to treatments.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced that its mmRNA device is now covered by Medicare, marking a significant milestone for the treatment of obstructive sleep apnea (OSA) and snoring. This acceptance by the Centers for Medicare & Medicaid Services (CMS) allows millions of Medicare beneficiaries to access this innovative non-surgical solution. The mmRNA device is designed to provide effective therapy for mild to moderate OSA, and enhances commercial insurance coverage prospects. Approximately 54 million Americans suffer from sleep apnea, with many undiagnosed.
FAQ
What is the current stock price of Vivos Therapeutics (VVOS)?
What is the market cap of Vivos Therapeutics (VVOS)?
